Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522574 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of XL019 in Adults With Myelofibrosis
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT00522574 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 100 participants.
The verdict
NCT00522574, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.
Interventions
- DRUG XL019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00522574
The ClinicalTrials.gov registry entry for NCT00522574 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL019 is the first listed.
NCT00522574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00522574 about?
NCT00522574 is a clinical study titled "A Safety Study of XL019 in Adults With Myelofibrosis". The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible tra...
What is the current status of trial NCT00522574?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2007-08.
What interventions are being tested in trial NCT00522574?
The interventions under investigation include: XL019 (DRUG).
Who is sponsoring clinical trial NCT00522574?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.